Bellatora Inc. Announces Name Change, Symbol Change and Reverse Stock Split October 3, 2016 OTC Disclosure
News Service Bellatora, Inc. (OTC Markets: ONCOD) (“Bellatora” or the “Company”), producer of premium quality electronic cigars, cigarillos, cigarettes and e-liquids for tobacco cessation, without tobacco combustion or harmful carcinogens, today announced that it has changed its name from Oncology Med, Inc. to Bellatora, Inc. The name change was effected to accurately reflect the Company’s primary line of business. In addition to the name change, the Company also changed its ticker symbol and recapitalized with a 1 - 1,500 reverse split. As a result of the stock split, the outstanding shares of the Company's common stock will decrease from 200,800,728 shares outstanding to approximately 40,099,990 shares outstanding. When applicable, fractional shares will be rounded up to the nearest whole share. The changes were approved by the Financial Industry Regulatory Authority effective September 28, 2016. The Company will trade under the symbol “ONCOD” for twenty business days, at which point, the symbol change will take effect and the Company’s common stock will trade under the symbol of “ECGR.”
Atom Miller, Chief Executive Officer of Bellatora, commented, “We are uniquely positioned with our premium quality products for Bellatora to become a major player in this industry. The name and symbol change better communicates our message and strategy of becoming a leading producer and supplier of premium quality electronic cigars, cigarillos, cigarettes and e-liquids. A key component to our defined strategy is to seek favorable acquisition candidates enjoying strategic market penetration which we seek to satisfy, while integrating others with our product offerings while combining them with our partnerships and successfully bringing them to market through our relationships and established sales channels. Going forward as Bellatora, Inc., we intend to continue to focus on markets with high potential for growth.”
The name change follows Bellatora LLC entering an Equity Exchange Agreement with Oncology Med, Inc., effective February 22, 2016. The final item to be completed under the Equity Exchange Agreement is the spin-off of Oncology Med, Inc.’s business and operations, which will continue to be run by its original management as a separate entity. In this way, those who invested in Oncology Med Inc. will retain the benefits of that investment, as well as their shares in Bellatora, Inc.
About Bellatora, Inc. - the company will be exploiting the Bellatora IP, including premium quality electronic cigars, cigarillos and cigarettes (“e-cigars”, “e-cigarillos”, and “e-cigarettes”) as well as liquids (“e-liquids”) for use in electronic ‘vaping’ devices. These products provide a non-intrusive and socially acceptable alternative to traditional combustible tobacco products, and often used to help consumers actively pursue tobacco cessation. Bellatora e-cigars and e-cigarettes are battery-powered devices that simulate tobacco smoking through inhalation of e-liquid vapor that may or may not contain nicotine, depending on customer preference. Inhalation of e-liquid vapor is accomplished without the traditional burning or tobacco, thus the consumer is not inhaling a vast array of chemical compounds and harmful carcinogens that occur through the combustion of traditional tobacco products. All this is achieved without the ash, or offending smell that is created by traditional combustible cigarettes. For additional information about Bellatora, please visit http://bellatoraecigars.com .
Forward-Looking Statements Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include projections of matters that affect revenue, operating expenses or net earnings; projections of growth; and assumptions relating to the foregoing. Such forward looking statements are generally qualified by terms such as: “plans, “anticipates,” “expects,” “believes” or similar words of like kind. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or qualified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. These factors are discussed in greater detail in the company’s business plan and filings with the OTC Markets Group.Posted by Bellatora Press 0 Comments